Evidence map›Paper›PMID 37102330›Full record

ArticleHuman vaccines & immunotherapeutics2023

Reduced reactogenicity of primary vaccination with DT3aP-HBV-IPV/Hib compared with DT2aP-HBV-IPV-Hib among infants: Mathematical projections in six countries.

Marina George, Jaime Pérez Martin, Mohammad AbdelGhany, Foteini Gkalapi, Nicolas Jamet, Richelle C Kosse, Yara Ruiz García, Elisa Turriani, Valérie Berlaimont

Open access · goldAbstract read
PubMed Full text at PMC Publisher
In one paragraph

Article in Human vaccines & immunotherapeutics, 2023. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 1 paper.

0numbers the graph read from it
0cells of the map it votes in
1citing papers in PubMed
0.6field-weighted citation impact, top 35% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

1 citing paper in PubMed, 2 citations in OpenAlex.

  1. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

9 authors at 3 institutions in 3 countries.

Marina GeorgeHari Group Limited, Greater Manchester, UK.ORCID 0000-0002-4054-8682
Jaime Pérez MartinMurcia Health Council, Murcia, Spain.ORCID 0000-0002-8794-4199
Mohammad AbdelGhanyGSK, Cairo, Egypt.ORCID 0000-0002-3342-9730
Foteini GkalapiGSK, Athens, Greece.ORCID 0000-0002-5611-6374
Nicolas JametGSK, Wavre, Belgium.ORCID 0000-0002-1980-9040
Richelle C KosseGSK, Amersfoort, The Netherlands.ORCID 0000-0001-9059-1278
Yara Ruiz GarcíaGSK, Tres Cantos, Spain.ORCID 0000-0003-4040-6139
Elisa TurrianiGSK, Wavre, Belgium.ORCID 0000-0002-0114-065X
Valérie BerlaimontGSK, Singapore, Singapore.ORCID 0000-0003-3850-4477
GlaxoSmithKline (Belgium) · BEHarman (United Kingdom) · GBServicio Murciano de Salud · ES

Funding

No grant is acknowledged in the PubMed record.

6 · The paper itself

Abstract

The hexavalent vaccines DT3aP-HBV-IPV/Hib and DT2aP-HBV-IPV-Hib are routinely used for primary immunization of infants against diphtheria, tetanus, pertussis, hepatitis B virus, poliomyelitis, and

Indexed as

Haemophilus influenzae type bHaemophilus VaccinesDiphtheria-Tetanus-Pertussis VaccineFeverHepatitis B VaccinesHepatitis B virusHumansImmunization ScheduleInfantPoliovirus Vaccine, InactivatedVaccinationVaccines, CombinedDiphtheria-Tetanus-Pertussis VaccineHaemophilus VaccinesHepatitis B VaccinesPoliovirus Vaccine, InactivatedVaccines, CombinedAbsolute risk reductionadverse reactionhexavalent vaccineinfantsreactogenicitysimulationvaccination

Identifiers

PMID37102330
PMCPMC10294728
OpenAlexW4367174770

What OpenQuestion holds

Textmetadata
LicenceCC BY-NC-ND
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.